Bank of America
KTTA icon

Bank of America’s Pasithea Therapeutics KTTA Stock Holding History

Bank of America’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-63
Closed -$81 – 6360
2025
Q4 		$81 Buy
63
+5
+9% +$4 ﹤0.01% 6860
2025
Q3 		$43 Sell
58
-4
-6% -$3 ﹤0.01% 8046
2025
Q2 		$44 Buy
62
+54
+675% +$59 ﹤0.01% 8126
2025
Q1 		$10 Hold
8
– – ﹤0.01% 8209
2024
Q4 		$25 Sell
8
-10
-56% -$35 ﹤0.01% 7985
2024
Q3 		$98 Buy
18
+12
+200% +$59 ﹤0.01% 7726
2024
Q2 		$30 Buy
+6
New +$39 ﹤0.01% 7932
2023
Q2 		– Hold
0
– -$3 – 7830
2023
Q1 		– Sell
-2
Closed -$23 – 7700
2022
Q4 		$21 Buy
+2
New +$40 ﹤0.01% 7976

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's KTTA Position: Q1 2026 in Review

Bank of America sold out of Pasithea Therapeutics (KTTA) in Q1 2026, closing a stake of 63 shares — an estimated $81 sold.

Bank of America first reported a position in KTTA in Q4 2022 and held it in 8 quarters. The position peaked at $98 in Q3 2024. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Bank of America reported no remaining Pasithea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 63 Pasithea Therapeutics shares in Q1 2026, an estimated $81.
  • Bank of America first reported a position in Pasithea Therapeutics in Q4 2022 and held it in 8 quarters.
  • Bank of America's Pasithea Therapeutics position peaked at $98 in Q3 2024.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.